Results 81 to 90 of about 7,233,987 (192)
A Diagnostic Dilemma: Hypophosphatemic Rickets Unmasking Tyrosinemia Type 1: A Case Report
ABSTRACT A 7.5‐year‐old Pakistani girl was misdiagnosed with hypophosphatemic rickets. Progressive skeletal deformities, hepatomegaly, and renal tubular dysfunction were detected despite standard treatment. Due to the atypical findings, genetic testing was performed and confirmed the diagnosis of Hereditary tyrosinemia Type 1.
Muhammad Wajid Siddique +5 more
wiley +1 more source
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta +2 more
wiley +1 more source
X-linked hypophosphatemia (XLH) is a rare X-linked dominant inherited disorder caused by loss-of-function variants in the PHEX gene and characterized by renal phosphate wasting, hypophosphatemia, abnormal vitamin D metabolism, growth retardation and ...
Maria Fourikou +8 more
doaj +1 more source
ABSTRACT Aim To compare the item difficulty and discriminative index of multiple‐choice questions (MCQs) generated by ChatGPT with those created by dental educators, based on the performance of dental students in a real exam setting. Materials and Methods A total of 40 MCQs—20 generated by ChatGPT 4.0 and 20 by dental educators—were developed based on ...
Nezaket Ezgi Özer +4 more
wiley +1 more source
Burosumab, a monoclonal antibody directed against the fibroblast growth factor 23 (FGF23), has been approved for the treatment of X-linked hypophosphatemia (XLH).
Manjunath Havalappa Dodamani +9 more
doaj +1 more source
Growth hormone treatment improves final height in children with X-linked hypophosphatemia
Background/aim Despite optimal conventional treatment (oral phosphate supplements and active vitamin D analogs), about 40–50% of children with well-controlled X-linked hypophosphatemia (XLH) show linear growth failure, making them less likely to achieve ...
Julia André +8 more
doaj +1 more source
ABSTRACT Vitamin D deficiency and secondary hyperparathyroidism (SHPT) are preventable causes of metabolic bone disease, yet they may remain clinically silent until catastrophic skeletal events occur. Chronic hepatitis B virus (HBV) infection has been increasingly linked to disordered bone and mineral metabolism, even in the absence of cirrhosis.
Walter Appati +3 more
wiley +1 more source
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Background: Mutations in fibroblast growth factor 23 (FGF-23) cause autosomal dominant hypophosphatemic rickets. Clinical and laboratory findings in this disorder are similar to those in oncogenic osteomalacia, in which tumors abundantly express FGF-23 ...
Hampson, G +15 more
core +1 more source
Hypertension is a characteristic complication of X-linked hypophosphatemia
X-linked hypophosphatemia (XLH) is a group of rare disorders caused by defective proximal tubular reabsorption of phosphate. Mutations in the PHEX gene are responsible for the majority of cases. There are very few reports of long-term complications of XLH other than skeletal and dental diseases.
Nakamura, Yoshie +4 more
openaire +3 more sources
Gingival and Periodontal Diseases and Conditions in Children and Adolescents: Consensus Report
ABSTRACT Background The objectives of this Focused Workshop were to update the epidemiology, aetiology, risk factors, diagnosis and management of gingival and periodontal diseases and conditions in children and adolescents, and to explore the applicability of the 2018 Classification in children and adolescents.
Iain Chapple +30 more
wiley +1 more source

